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Abstract
Background: There is insufficient evidence on the effectiveness of acupuncture for irritable bowel syndrome (IBS) for 
conclusions to be drawn. Given the current interest in acupuncture by patients, it is in the public interest to establish 
more rigorous evidence. Building on the positive findings from a pilot study, in this paper we present the protocol for a 
fully-powered trial designed to establish whether or not acupuncture is effective and cost-effective.
Methods/Design: In this pragmatic randomised controlled trial we will randomise patients recruited directly from GP 
databases to either 10 sessions of acupuncture plus usual GP care or to usual GP care alone. The primary clinical 
outcome will be the IBS Symptom Severity Score (SSS) (maximum score 500) at three months, and at 12 month 
assessing whether there is an overall benefit. We estimate the sample size required to detect a minimum clinical 
difference at 90% power and 5% significance to be 188 patients. To allow for loss to follow up we will recruit 220 
patients drawn from an estimated primary care population of 140 000. Analysis will be by intention-to-treat, and 
multiple imputation is to be used for missing data.
In a nested qualitative study using in-depth interviews, we will explore how patients, acupuncturists, and GPs explain
and subsequently understand acupuncture to work. We will use purposive sampling to identify patients and flexible
topic guides for the interviews. The data analysis will lead to a thematic description of how patients and practitioners
explain how acupuncture works, and whether or not the explanations influence treatment outcome and/or referrals.
We will undertake a cost-effectiveness analysis at 12 months by comparing resource use in the two groups with any
treatment benefit. We will use the EQ-5D to measure health-related quality of life and convert into quality adjusted life
years (QALYs). We will generate cost effectiveness acceptability curves (CEACs) exploring the probability that
acupuncture will produce an acceptable cost per QALY at different cost-effectiveness thresholds.
Discussion: The trial has received NHS ethics approval and recruited 233 patients between November 2008 and June 
2009. Results are expected in 2011.
Trial Registration: Current Controlled Trials ISRCTN08827905
Background
Irritable bowel syndrome (IBS) is the most common dis-
order encountered by gastroenterologists and the most
common functional bowel disorder seen by doctors in
primary care [1]. The causes of the disorder are unknown
but sufferers are said to experience an increased gastroin-
testinal stress response consistent with an up-regulation
in neural processing between the gut and the brain,
termed the "brain-gut axis" [2]. Irritable bowel syndrome
is thought to be exacerbated by psychosocial stressors, so
treatment is most successful when a multi-component,
comprehensive approach is used. Therefore usual care
involves a number of interventions as options, including
pharmaceuticals, psychological interventions and dietary
changes. According to a Cochrane review, bulking agents
* Correspondence: hm18@york.ac.uk
1 Department of Health Sciences, University of York UK
Full list of author information is available at the end of the articleMacPherson et al. BMC Gastroenterology 2010, 10:63
http://www.biomedcentral.com/1471-230X/10/63
Page 2 of 5
and antidepressants lack a clear benefit in treating IBS,
while antispasmodics, as a category, provide relief of
abdominal pain [3]. A review of conventional treatments
found that they are rarely effective in managing IBS
symptoms [4], a finding that is supported by the
Cochrane review [3]. Conventional treatments for IBS are
associated with risks including adverse events, worsening
of symptoms, and financial costs [5]. The direct and indi-
rect costs associated with IBS are potentially considerable
[6]. Some patients are satisfied with current therapies,
but many others are frustrated, feeling that advice lacks
clarity, conflicts with other GPs' advice and may not work
[7].
I n  t h i s  c o n t e x t  i t  i s  n o t  s u r p r i s i n g  t h a t  p a t i e n t s  a r e
increasingly turning to complementary and alternative
m edicin e [8] .  An est im a t ed 10% of  t he  UK po pula t ion
uses complementary and alternative medicine [9]. Alter-
native and complementary techniques are used by
between 11% and 43% of patients with gastrointestinal
disorders [10]. A survey of GPs found that there is an
"effectiveness gap" in currently available treatments in
primary care for IBS [11]. Among acupuncture patients,
5% state that their primary complaint is gastrointestinal,
most commonly IBS [12]. According to a recent
Cochrane review of acupuncture for IBS, the studies to
date are of poor quality, heterogeneous in terms of inter-
ventions, controls and outcomes, and therefore provide
insufficient evidence to determine if acupuncture is an
effective treatment for IBS [13]. A recent safety survey of
patient reports over a three month period found that acu-
puncture treatments performed by competent practitio-
ners are rarely associated with adverse events [14].
In this study, we used our pilot study
(ISRCTN32823720) as a platform to design a full-scale
trial of acupuncture in order to provide robust evidence
on acupuncture as a potential referral option in primary
care. The primary objective is to establish rigorous evi-
dence of the clinical effectiveness and cost-effectiveness
of acupuncture plus usual GP care when compared to
usual GP care alone for patients with irritable bowel syn-
drome (IBS) in primary care. The secondary objective is
to perform a qualitative exploration of the experience of
patients, GPs and acupuncturists in using acupuncture to
treat irritable bowel syndrome.
Methods/Design
We will conduct a parallel-arm randomised controlled
trial to determine the effectiveness and cost-effectiveness
of acupuncture plus usual care compared to usual care
alone for the treatment of IBS. The rationale for this
unblinded pragmatic design is that it will best answer
practical questions regarding the clinical and cost impli-
cations of offering acupuncture as an additional treat-
ment option within primary care [15]. This trial design
will not ascertain the extent that 'placebo' effects contrib-
ute to the overall outcome. This design will not be able to
ascertain the contribution to the overall effect from
expectation, belief and other non-specific factors such as
time and attention. In pragmatic terms, even if some of
the effect of the treatment process is due to "placebo",
acupuncture cannot be delivered without it, and there-
fore as with all complex interventions, the important
question is whether the overall effect is worth paying for.
For patients the primary objective is an improvement in
outcome and the contribution of a placebo effect to that
improvement is immaterial. The pragmatic trial design
provides a real-world comparison to be made for a cost-
effectiveness analysis and is directly relevant to policy
and decision-makers.
Nested within the trial is a qualitative analysis designed
to explore how patients, acupuncturists, and GPs explain
and subsequently understand acupuncture to work. The
qualitative aspect of this study is designed using a phe-
nomenological approach. Phenomenology is the study of
how people describe and experience phenomena, which
in this case is acupuncture [16]. The design fulfils a basic
and summative evaluation purpose, in that the study will
contribute to general knowledge and determine useful-
ness [17].
Participant recruitment criteria
To recruit participants, we will use the 'database' recruit-
ment method as we did for the pilot [18]. Participants will
be identified via the databases of GP practices in the NHS
North Yorkshire & York Primary Care Trust. Our inclu-
sion criteria are that participants must be aged 18 or
older, with a diagnosis of IBS from their GP. We will
exclude participants who do not speak English, who score
less than 100 on the IBS Symptom Severity Score (SSS)
[19], who have a current diagnosis of haemophilia, hepa-
titis, HIV, or cancer, who have had major gastrointestinal
surgery in the previous six months, who are pregnant,
who have a history of psychosis or substance abuse, or
who are receiving acupuncture at the time. Participants
will be assessed for IBS using the Rome III criteria [20]. In
our pilot study, based in Birmingham, 32 eligible partici-
pants consented to participate from four GP practices
that together had a registered list size of 20,300 [18]. For
the proposed research, we estimate that 220 participants
are needed (see below for sample size justification). To
recruit this number, we will need a total primary care list
size of approximately 140,000 patients, equivalent to 14
GP practices with an average of 10,000 patients each. We
plan to recruit GP practices in geographically contained
groups, such that each group of practices is located near a
clinic that provides acupuncture from qualified acupunc-MacPherson et al. BMC Gastroenterology 2010, 10:63
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turists. These groups are likely to be in the larger centres
of population in the region. Based on our pilot, we esti-
mate that recruitment will take 12 months.
Randomisation and blinding
We will randomise participants to receive either a short
course of traditional acupuncture plus usual GP care or
usual GP care alone, using simple concealed randomisa-
tion, the most robust method of avoiding possible selec-
tion bias [21]. The randomisation sequence will be
computer generated at the University of York by an inde-
pendent data manager at the York Trials Unit, and con-
cealed from the researcher who will subsequently inform
participants of their allocation. For those participants
allocated to acupuncture, the selection of an acupuncture
practitioner will be made by appointment availability and
convenience for the participant. As this is a pragmatic
trial, neither participants nor researchers will be blind to
treatment allocation. Whilst randomisation eliminates
selection bias, there are other sources of bias we need to
avoid. To assess the impact of participant preferences, we
propose to ask participants at baseline for their treatment
preferences [22]. To avoid bias due to attrition, partici-
pants in both groups will be followed up carefully. Partic-
ipants will also be given £5 as an incentive to complete
the final follow-up questionnaire (they will receive the
incentive whether or not they actually complete the
forms) in order to reduce attrition rates. Incentives such
as this have been shown to improve follow-up rates [23].
Interventions
Acupuncture will be provided by professional acupunc-
turists who are registered with the British Acupuncture
Council, and have at least three years' experience. The
acupuncture will be provided at independent clinics that
are geographically near the GP practices from which we
are recruiting. The participants in this group will be
offered up to 10 treatment sessions over a three month
period. Acupuncturists will be trained to follow a treat-
ment protocol adapted from the one that was tested by
acupuncturists taking part in the pilot trial [18]. The
treatment protocol allows sufficient standardisation to
assist replication, yet is flexible enough to allow individu-
alised treatments. Adherence to the protocol will be
monitored through the use of practitioner logs, which
will be collected throughout the trial. In terms of compli-
ance, we expect to obtain similar levels to those achieved
in our pilot in which, on average, patients allocated acu-
puncture took up eight of the ten sessions offered. All
patients will remain under the care of their general prac-
titioner and will continue to receive their usual NHS
treatment. Both groups will be able seek care elsewhere
according to need. We will collect and report information
from patients in both groups at three, six, nine and 12
months regarding usual care and treatments they have
received.
Outcome measures
Our primary outcome measure will be the IBS Symptom
Severity Score (IBS SSS). This questionnaire is scored
from 0 to 500 (< 75 = no IBS, 75-175 = mild case, 175-300
= moderate and 300+ = severe), and has been validated
for use in IBS patients [19]. Our secondary outcomes will
be the IBS Non-Colonic Symptom Score (which includes
lethargy & tiredness, "wind", backache, and other symp-
toms) [24], the SF-12 to evaluate patients' health related
quality of life [25], and the Hospital Anxiety and Depres-
sion Scale [26]. The primary outcome for the cost-effec-
tiveness component of the study will be EQ-5D [27]. We
will also collect data on medication use, health services
used and days lost from work. Along with baseline data,
a l l  o u t c o m es  wi l l  be  s o u gh t  b y  po s t a l  q u e s t i o n n a i r e  a t
three, six, nine and 12 months, and where this fails, the
main outcome measure will be sought by telephone. We
will also seek information associated with hospitalisa-
tions. Open text questions will be used to gather qualita-
tive data on patient experiences of acupuncture,
including adverse events. We will also collect data on
safety and treatment processes from log books completed
by the acupuncturists. We will use in-depth interviews
with flexible topic guides to collect qualitative data.
Sample size required
The sample size required for a full-scale trial is based on a
minimal clinical difference of 50 points on the primary
outcome measure the IBS Symptom Severity Score [19].
A residual standard deviation of 90 points was observed
in our pilot [18], and taking into account potential sam-
pling bias [28] by using a one-sided 90% confidence inter-
val for the variance, we estimate an adjusted standard
deviation to be 105 points. Using this estimate, the sam-
ple size required to detect a difference at 90% power and
5% significance level is 188 patients in a two-arm trial. To
allow for loss to follow up, of a similar proportion
observed in the pilot, our proposed trial requires 220
patients.
For the nested qualitative study, we will collect data
from 30 patients, a sample size that is likely to be suffi-
cient to map the diversity of patients in primary care [29].
We will use purposive sampling guided by a matrix based
on gender, intervention, preference, and baseline IBS
severity as illustrated below in Table 1.
We will also collect qualitative data from 10 GPs and 10
acupuncturists using convenience samples of practitio-
ners in North Yorkshire, excluding those involved in the
trial. It has been suggested that a sample size of 10 is ade-
quate for phenomenological studies because researchers
are seeking common features of experience [30].MacPherson et al. BMC Gastroenterology 2010, 10:63
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Data analysis
We will use intention to treat analysis; all participants will
be included in their randomised groups, whether or not
they have received their allocated treatment. The primary
outcome will be the IBS SSS at three months, using analy-
sis of covariance while adjusting for baseline scores and
GP practice, and at 12 months, using multi-level model-
ling with IBS SSS scores at 3 month intervals. Sensitivity
to missing outcomes data will be addressed using multi-
ple imputation. We will also compare between groups the
secondary outcomes of IBS non-colonic symptom scores,
quality of life (SF-12) and anxiety and depression
(HADS). As a secondary analysis, we will explore the
interaction between the effect of acupuncture and vari-
ables assessed prior to randomisation: participants' belief
in acupuncture, expectations that acupuncture will help
their IBS (expectation), patient treatment preference and
whether patients received their preferred treatment or
not. Further secondary analyses will investigate the
effects of variation in outcome between acupuncturists.
For the qualitative data, we will transcribe the inter-
views, identify recurring themes and develop a concep-
tual framework to apply to the complete data set. Data
analysis will be conducted by two researchers working
independently to ensure a thorough analysis. Synthesised
data will provide a thematic description of how patients
and practitioners understand and explain acupuncture to
work, and whether or not this explanation influences
treatment outcome and/or referrals.
Cost effectiveness
We will undertake a cost-effectiveness analysis at 12
months by comparing resource use in the two groups
with any treatment benefit in an incremental cost-effec-
tiveness ratio. The primary analysis will calculate cost-
effectiveness from an NHS perspective because of the
potential to influence health policy. However, we will also
perform cost-effectiveness calculations from a societal
perspective to ensure that this research will not be lim-
ited in its usefulness. We will collect data from patients
and GPs about patients' resource use, such as visits to
their GP, visits to other health providers, both within and
outside the NHS and medication use, as well as measur-
ing their days off and whether usual activities are affected
by their IBS. We will use EQ-5D to measure health-
related quality of life and convert into quality adjusted life
years (QALYs), in order to calculate an incremental cost
effectiveness ratio (cost per QALY gained), after adjusting
for baseline EQ-5D score [31]. To measure presenteeism
and absenteeism, we will use the Work Productivity and
Activity Impairment instrument (WPAI) and convert the
scores into a monetary value [32]. We will also use a net
monetary benefit approach to generate cost effectiveness
acceptability curves (CEACs) exploring the probability
that acupuncture will produce an acceptable cost per
QALY at different cost-effectiveness thresholds. This
approach accounts directly for uncertainty around the
estimates of costs and effects, which is particularly
important as this trial is powered on the basis of the clini-
cal effectiveness measure (IBS SSS) rather than the eco-
nomic outcome measure (EQ-5D). If the intervention is
found to be not cost-effective at 12 months, then evalua-
tion over a longer time frame may be considered.
Discussion
The proposed research received ethics approval from the
York Research Ethics Committee (08/H1311/66). The
trial recruited 233 patients between November 2008 and
June 2009. Written informed consent has been obtained
from all participants. Published results are expected in
2011.
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